Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.35 |
| ▸ | TUBB | P07437 | 2/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122304 | 0.93 | CSNK2A1 (0.43) | RAF1BRAFEGFRERBB2SYK | |
| SCHEMBL2124457 | 0.90 | RAF1 (0.38) | RAF1BRAFEGFRERBB2SYK | |
| SCHEMBL2124727 | 0.86 | SRC (0.44) | BRAFEGFRGAKSRCCSNK2A1 | |
| SCHEMBL2123111 | 0.83 | CSNK2A1 (0.47) | EGFRERBB2GAKSRCCSNK2A1 | |
| SCHEMBL2125438 | 0.82 | KDR (0.41) | BRAFGAKTBK1 | |
| SCHEMBL2126389 | 0.82 | ALDH1A1 (0.47) | BRAFFYNEGFRERBB2SRC | |
| SCHEMBL2123211 | 0.82 | TP53 (0.38) | FYNCSNK2A1PTK2MAPTTUBB4A | |
| SCHEMBL2124785 | 0.81 | BRAF (0.46) | BRAFFYNEGFRERBB2CSNK2A1 | |
| SCHEMBL18686163 | 0.81 | NPC1 (0.37) | FYNCSNK2A1PTK2MAPTXDH | |
| SCHEMBL2124547 | 0.81 | MAPT (0.42) | BRAFEGFRERBB2SYKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | claimed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | claimed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | claimed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-06 | — | — | US | disclosed |
| EP-2827890-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | The University of Queensland (AU) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013138871-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-09-26 | — | — | WO | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | HLA-DRB1, CD74, CHI3L1 | RAF1 4404/4885BRAF 4825/4885FYN 3186/4885 |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | RAF1 309/4885BRAF 280/4885FYN 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.